Antibodies News and Research

RSS

PrEP shown to be safe and effective for widespread use

New research presented at the HIV Drug Therapy Conference in Glasgow today shows that pre-exposure prophylaxis could be given to millions of people worldwide with no increased risk of safety issues during treatment.

30 Oct 2018

Scientists find ways to block nitration of amino acids to improve cancer immunotherapy

Immunotherapy -- harnessing T-cells to attack cancer cells in the body -- has given hope to patients who endure round after round of treatment, including chemotherapy, to little effect. For all of its promise, however, immunotherapy still benefits only a minority of patients -- a reality driving research in the field for ways to improve the relatively new approach.

30 Oct 2018

Scientists discover cell adhesion mechanism used by mycoplasma genitalium

Researchers from the Molecular Biology Institute of Barcelona and the Institute of Biotechnology and Biomedicine have discovered the mechanism by which the bacterium Mycoplasma genitalium) adheres to human cells.

29 Oct 2018

New approach may lead to protective vaccines for immunocompromised patients

A study led by Som Nanjappa at the University of Illinois College of Veterinary Medicine identifies a cellular target that may improve efficacy in vaccines designed to protect immunocompromised individuals from potentially deadly opportunistic infections.

26 Oct 2018

Researchers study significance of water in a promising cancer biomarker

The UPV/EHU's Department of Physical Chemistry and the Biofísika Institute have conducted a multidisciplinary study of the Tn antigen that appears in 90% of cancers. Two variants that appear to be similar but which have very different shapes in water have been studied.

26 Oct 2018

Raman microscopy can help detect cancer drug resistance

Biophysicists at Ruhr-Universität Bochum have demonstrated that Raman microscopy can be used to detect the resistance of tumor cells to cancer drugs.

26 Oct 2018

New method to block immunosuppression in cancer discovered

Belgian research groups from the UCLouvain and WELBIO, VIB and Ghent University, and the biotechnology company argenx elucidated the three-dimensional structure of an assembly of proteins operating on cells that dampen immune responses

26 Oct 2018

Scientists identify new target for battling deadly form of leukemia

UT Southwestern scientists, working with colleagues at a sister institution in Houston, have identified a new target for battling a deadly form of leukemia.

24 Oct 2018

Study uncovers rare phenomenon of antibodies working together against malaria

Scientists investigating how the human immune system defends against malaria have uncovered a rare phenomenon: antibodies working together to bind to a vulnerable spot on the parasite.

24 Oct 2018

Simple technology prevents infectious disease outbreaks in low-resource settings

A pilot study in which healthcare workers in the Central African Republic used a smartphone app to transmit public health disease reports to health authorities demonstrates that this technique contributes to early detection and prevention of infectious diseases and outbreaks.

24 Oct 2018

Innovative computer software sheds new light on genetic processes underlying deadly diseases

Innovative computer software developed by University of Leicester scientists is shedding new light on the genetic makeup of deadly pathogens responsible for meningitis and gastroenteritis.

23 Oct 2018

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF-β pathways, today announced that the first patient has been dosed in a Phase 2a trial evaluating the efficacy and safety of AVID100 in patients with squamous non-small cell lung cancer whose tumors overexpress epidermal growth factor receptor.

23 Oct 2018

Common antibodies associated with myocardial infarction

Levels of antiphospholipid antibodies, which are associated with rheumatic diseases, are also elevated in myocardial infarction without any autoimmune co-morbidity, a study from Karolinska Institutet in Sweden published in The Annals of Internal Medicine reports.

23 Oct 2018

Researchers discover how acne-causing bacteria resist treatment

Researchers in Sweden have discovered how acne-causing bacteria feed off their human hosts. The study, which was performed at KTH Royal Institute of Technology, could make it possible to find effective ways to treat severe acne.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Researchers produce artificial antibody capable of blocking prions in the laboratory

Prion diseases affect the brain, causing neurodegenerative problems that always lead to death. They attracted attention in the late 1990s due to the "Mad Cow" scare.

22 Oct 2018

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.

22 Oct 2018

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Could we prevent Alzheimer's disease by treating herpes?

An exciting new paper suggests that over half of all cases of Alzheimer’s disease could be traced back to herpes simplex virus 1, which causes cold sores.

19 Oct 2018

URMC researchers discover new approach to deliver therapeutics to the brain

Researchers at the University of Rochester Medical Center have discovered a potentially new approach to deliver therapeutics more effectively to the brain. The research could have implications for the treatment of a wide range of diseases, including Alzheimer's, Parkinson's, ALS, and brain cancer.

19 Oct 2018

Antibodies News and Research

PrEP shown to be safe and effective for widespread use

Scientists find ways to block nitration of amino acids to improve cancer immunotherapy

Scientists discover cell adhesion mechanism used by mycoplasma genitalium

New approach may lead to protective vaccines for immunocompromised patients

Researchers study significance of water in a promising cancer biomarker

Raman microscopy can help detect cancer drug resistance

New method to block immunosuppression in cancer discovered

Scientists identify new target for battling deadly form of leukemia

Study uncovers rare phenomenon of antibodies working together against malaria

Simple technology prevents infectious disease outbreaks in low-resource settings

Innovative computer software sheds new light on genetic processes underlying deadly diseases

Forbius initiates Phase 2a trial evaluating efficacy, safety of AVID100 in patients with squamous NSCLC

Common antibodies associated with myocardial infarction

Researchers discover how acne-causing bacteria resist treatment

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Researchers produce artificial antibody capable of blocking prions in the laboratory

Takeda presents vedolizumab phase 3 VISIBLE 1 trial results for treatment of moderately to severely active ulcerative colitis

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Could we prevent Alzheimer's disease by treating herpes?

URMC researchers discover new approach to deliver therapeutics to the brain

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo